Prilenia Neurotherapeutics Ltd.

Prilenia Therapeutics Development Ltd.

Eli Eyal

Merav Bassan

Anna Kristina Sveinsdotter Teige Wickenberg

Beth E Borowsky

Michael Hayden

Juha-Matti Savola

Spyridon Papapetropoulos

Igor D Grachev

Esther Lukasiewicz Hagai

Mark Forrest Gordon

Esther Lukasiweicz Hagai

A method of treating a human patient afflicted with Huntington's disease, comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine, its analog or a pharmaceutically acceptable salt thereof.

Pridopidine for treating Huntington's disease

The invention provides a method of treating a subject afflicted with a dystonia, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.

Use of pridopidine for treating dystonias

This invention provides a method of maintaining functional capacity, improving functional capacity, or lessening the decline of functional capacity in a human patient comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine such that a dose of 90-225 mg of pridopidine is administered to the patient per day, so as to thereby maintain functional capacity, improve functional capacity, or lessen the decline of functional capacity in the human patient.

Use of pridopidine for treating functional decline

Pridopidine for treating huntington's disease

A method of treating a human patient afflicted with Huntington's disease, comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof such that greater than 90 mg of pridopidine is administered to the patient per day.

Use of pridopidine for treating Huntington's disease

Growing community of inventors

Petah-Tikva, Israel

Eli Eyal